Please note that the ANZCTR website will be unavailable from 9am until 9.30am (AEST) on Monday 22nd July for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02585895




Registration number
NCT02585895
Ethics application status
Date submitted
7/10/2015
Date registered
26/10/2015
Date last updated
19/09/2017

Titles & IDs
Public title
Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment
Scientific title
A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
Secondary ID [1] 0 0
2015-001343-37
Secondary ID [2] 0 0
20140316
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hypercholesterolemia 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Evolocumab
Treatment: Surgery - Low-density Lipoprotein Cholesterol (LDL-C) Apheresis

Experimental: Evolocumab - Participants received 140 mg evolocumab every 2 weeks (Q2W) administered by subcutaneous injection for 6 weeks during the primary period of the study. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.

Active Comparator: Low Density Lipoprotein Cholesterol (LDL-C) Apheresis - Participants continued apheresis at the same schedule, every week (QW) or every two weeks (Q2W), as prior to study entry, for the first 6 weeks. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.


Other interventions: Evolocumab
Administered by subcutaneous injection once every 2 weeks

Treatment: Surgery: Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
Participants received apheresis for LDL-C according the their physician's prescription and local custom.

Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Surgery
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Apheresis Avoidance at the End of Randomized Therapy - Avoidance of apheresis at end of randomized therapy was defined as no apheresis at week 5 and week 6. Aperesis at weeks 5 or 6 was based on LDL-C level at week 4:
participants with LDL-C = 100 mg/dL at week 4 received apheresis at week 5 (participants who received apheresis QW before study entry) or week 6 (participants who received apheresis Q2W prior to study entry). If LDL-C was < 100 mg/dL at week 4, no apheresis was performed at week 5 or week 6, irrespective of assigned treatment group.
Participants who ended the study prior to week 6 were considered as not achieving apheresis avoidance.
Timepoint [1] 0 0
Week 5 and week 6
Secondary outcome [1] 0 0
Percent Change From Baseline in Low-density Lipoprotein Cholesterol
Timepoint [1] 0 0
Baseline and week 4
Secondary outcome [2] 0 0
Percent Change From Baseline in Non-high-density Lipoprotein-Cholesterol
Timepoint [2] 0 0
Baseline and Week 4
Secondary outcome [3] 0 0
Percent Change From Baseline in Total Cholesterol/High-density Lipoprotein Cholesterol Ratio
Timepoint [3] 0 0
Baseline and Week 4

Eligibility
Key inclusion criteria
- Male or female, = 18 years of age

- Subject has been receiving regular apheresis for LDL-C lowering for at least 3 months
immediately prior to lipid screening and has a treatment goal of LDL-C < 100 mg/dL
(2.6 mmol/L), and has been receiving LDL-C apheresis during the last = 4 weeks prior
to lipid screening at regular QW or Q2W schedule and with no changes in apheresis type

- Subject is receiving lipid-lowering pharmacological background therapy which includes
a high-intensity statin dose (moderate-intensity statin dose with attestation that a
higher dose is not appropriate for the subject) unless the subject has a history of
statin intolerance

- Lipid-lowering therapy status (ie, any therapy for lowering lipids, including
apheresis type and frequency) must be unchanged for = 4 weeks prior to LDL-C screening

- Pre-apheresis LDL-C is = 100 mg/dL (= 2.6 mmol/L) and = 190 mg/dL (= 4.9 mmol/L) at
screening

- Fasting triglycerides = 400 mg/dL (4.5 mmol/L) at screening.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

- Known homozygous familial hypercholesterolemia

- Missing any apheresis session is medically contraindicated or inappropriate

- Stopping apheresis would be inappropriate in the opinion of the investigator even if
LDL-C is controlled to < 100 mg/dL with other therapies

- Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI),
coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization.

- Uncontrolled hypertension

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Research Site - Heidelberg
Recruitment postcode(s) [1] 0 0
3084 - Heidelberg
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida
Country [2] 0 0
United States of America
State/province [2] 0 0
Kansas
Country [3] 0 0
United States of America
State/province [3] 0 0
Michigan
Country [4] 0 0
United States of America
State/province [4] 0 0
Oregon
Country [5] 0 0
Czechia
State/province [5] 0 0
Hradec Kralove
Country [6] 0 0
France
State/province [6] 0 0
Bron
Country [7] 0 0
France
State/province [7] 0 0
Nantes Cedex 1
Country [8] 0 0
Germany
State/province [8] 0 0
Berlin
Country [9] 0 0
Germany
State/province [9] 0 0
Dresden
Country [10] 0 0
Germany
State/province [10] 0 0
Düsseldorf
Country [11] 0 0
Germany
State/province [11] 0 0
Flensburg
Country [12] 0 0
Italy
State/province [12] 0 0
Pisa
Country [13] 0 0
Italy
State/province [13] 0 0
Roma
Country [14] 0 0
Spain
State/province [14] 0 0
Andalucía
Country [15] 0 0
United Kingdom
State/province [15] 0 0
Harefield
Country [16] 0 0
United Kingdom
State/province [16] 0 0
Penarth

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Amgen
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
To evaluate the efficacy of subcutaneous (SC) evolocumab, compared to regularly scheduled
low-density lipoprotein cholesterol (LDL-C) apheresis, on reducing the need for future
apheresis.
Trial website
https://clinicaltrials.gov/show/NCT02585895
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
MD
Address 0 0
Amgen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications